MycRX Pharma

MycRX is a Melbourne-based biotechnology company dedicated to the discovery and development of small molecule inhibitors targeting the MYC oncoprotein. MYC is a master regulator of cancer cell proliferation and is deregulated in approximately 70% of all human cancers, yet it has long been considered an undruggable target. The company leverages deep expertise in MYC biology and structural chemistry, originating from the Walter and Eliza Hall Institute (WEHI) and the Peter MacCallum Cancer Centre. MycRX's lead programs aim to disrupt the MYC-MAX transcription factor complex to treat a broad range of solid and hematological tumors. By targeting this central node in cancer signaling, the company seeks to provide new therapeutic options for patients with high-unmet-need malignancies.